Nxera Pharma has launched a broad proprietary pipeline focused on next-generation therapies for obesity and related metabolic ...

Porosome Therapeutics has announced major advances in Alzheimer’s disease research, including FDA validation of ...

Everest Medicines has announced a strategic equity investment of US$30.9 million in I-Mab, acquiring 15,846,154 newly issued ...

Microbiotica has completed patient recruitment for its phase 1b trial, COMPOSER-1, evaluating MB310 in adults with ulcerative ...

Scientists at the University of Bath have developed a new technology that could allow protein-based drugs to be taken orally, potentially replacing injections for treatments such as growth hormone, ...

AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) ...

Moderna has received marketing authorisation from the European Commission for its updated COVID-19 vaccine, Spikevax, which ...

Alfasigma has announced positive topline results from its OLINGUITO phase 3 trial evaluating filgotinib in adults with active ...

Moderna has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Exonate has announced plans to initiate a phase 2b clinical trial of its lead candidate EXN407, a topical SRPK1 inhibitor, ...

PhoreMost has published new data validating its GlueSEEKER platform, a high-throughput technology designed to accelerate ...

Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in ...